Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07311850 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
A Phase 3 study of Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3,500
- Enrollment target
- 5
- Study locations
NCT07311850: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
NCT07311850 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 3,500 participants, above the 336-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (942% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07311850, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,500 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MET097
Study Locations (5)
California
- Research Site 97301-001007 - Riverside
- Research Site 97301-001070 - Torrance
Colorado
- Research Site 97301-001077 - Englewood
Florida
- Research Site 97302-001001 - Hollywood
North Carolina
- Research Site 97301-001309 - Cary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
What NCT07311850 shows while recruiting
NCT07311850 is an interventional study that assigns participants to a tested intervention. Its 3,500 participants enrollment target places it among the larger protocols in the corpus, above the 336-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (942% higher).
The record links to 1 condition, with Obesity and Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07311850 lists 5 locations in 4 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT07311850 about?
NCT07311850 is a clinical study titled "Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity". This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with t...
What is the current status of trial NCT07311850?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,500 participants. The study started on 2025-12-29. Estimated completion is 2028-05.
What conditions does trial NCT07311850 study?
This clinical trial studies the following conditions: Obesity and Overweight.
What interventions are being tested in trial NCT07311850?
The interventions under investigation include: Placebo (DRUG), MET097 (DRUG).
Who is sponsoring clinical trial NCT07311850?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07311850 being conducted?
This trial has 5 study locations across California, Colorado, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07311850's enrollment target sits among peer trials
3,500 2nd of 27 the highest of 27 other Obesity and Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
RECRUITING · Phase 1
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
-
Weight Management Intervention in College: A Pilot
RECRUITING · NA
-
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI